Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Julie Terzic; Amanda Seipel; Jean Dubuisson; Jean-Christophe Tille; Petros Tsantoulis; Alfredo Addeo; S Intidhar Labidi-Galy

doi:10.1016/j.gore.2020.100600

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Gynecol Oncol Rep. 2020 Jun 15:33:100600. doi: 10.1016/j.gore.2020.100600. eCollection 2020 Aug.

Authors

Julie Terzic¹, Amanda Seipel², Jean Dubuisson³, Jean-Christophe Tille², Petros Tsantoulis^{1

4}, Alfredo Addeo¹, S Intidhar Labidi-Galy^{1

4}

Affiliations

¹ Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
² Department of Diagnosis, Division of Clinical Pathology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
³ Department of Woman, Child and Adolescent, Division of Gynecology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
⁴ Department of Medicine, Faculty of Medicine, University of Geneva, Genève, Switzerland.

Abstract

•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8⁺ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Keywords: CCL5; CD8; CSMD3; CXCL9; High-grade serous ovarian carcinoma; Immunotherapy; PD1; Pembrolizumab.

Publication types

Case Reports